Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, Stockner H, Gaenslen A, Mahlknecht P, Huber H, Srulijes K, Klenk J, Fassbender K, Maetzler W, Poewe W (2013) The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 20:102–108

Article  CAS  PubMed  Google Scholar 

Birkmayer W, Hornykiewicz O (1961) The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 73:787–788

CAS  PubMed  Google Scholar 

Birkmayer W, Mentasti M (1967) Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes). Arch Psychiatr Nervenkr 210:29–35

Article  CAS  PubMed  Google Scholar 

Cadar D, Jellinger KA, Riederer P, Strobel S, Monoranu CM, Tappe D (2021) No Metagenomic evidence of causative viral pathogens in postencephalitic parkinsonism following encephalitis lethargica. Microorganisms 9:1716

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardoso F, Goetz CG, Mestre TA, Sampaio C, Adler CH, Berg D, Bloem BR, Burn DJ, Fitts MS, Gasser T, Klein C, de Tijssen MAJ, Lang AE, Lim SY, Litvan I, Meissner WG, Möllenhauer B, Okubadejo N, Okun MS, Postuma RB, Svenningsson P, Tan LCS, Tsunemi T, Wahlström-Helgren S, Gershanik OS, Fung VSC, Trenkwalder C (2023) A Statement of the MDS on biological definition, staging, and classification of Parkinson’s disease. Mov Disord 9:259–266

Google Scholar 

Gad SN, Nofal S, Raafat EM, Ahmed AAE (2020) Lixisenatide reduced damage in hippocampus CA1 neurons in a rat model of cerebral ischemia-reperfusion possibly via the ERK/P38 signaling pathway. J Mol Neurosci 70:1026–1037

Article  CAS  PubMed  Google Scholar 

Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39

Article  CAS  PubMed  Google Scholar 

Grünblatt E, Bartl J, Zehetmayer S, Ringel TM, Bauer P, Riederer P, Jacob CP (2009) Gene expression as peripheral biomarkers for sporadic Alzheimer’s disease. J Alzheimers Dis 16:627–634

Article  PubMed  Google Scholar 

Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Müller T, Wenning GK (2006) Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol 29:322–330

Article  PubMed  Google Scholar 

Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE (2024) A biological classification of Parkinson’s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23:191–204

Article  PubMed  Google Scholar 

Horvath K, Aschermann Z, Acs P, Deli G, Janszky J, Komoly S, Balazs E, Takacs K, Karadi K, Kovacs N (2015) Minimal clinically important difference on the motor examination part of MDS-UPDRS. Parkinsonism Relat Disord 21:1421–1426

Article  PubMed  Google Scholar 

Irfan H, Muneer SU, Maheshwari AB, Kumar N, Iftikhar S (2024) Lixisenatide in early Parkinson’s disease: efficacy, safety, and future directions: a correspondence. Neurosurg Rev 47:232

Article  PubMed  Google Scholar 

Isaacson SH, Pagan FL, Lew MF, Pahwa R (2022) Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord 7:100161

PubMed  PubMed Central  Google Scholar 

Koller WC, Herbster G (1987) Adjuvant therapy of parkinsonian tremor. Arch Neurol 44:921–923

Article  CAS  PubMed  Google Scholar 

LeWitt PA, Stocchi F, Arkadir D, Caraco Y, Adar L, Perlstein I, Case R, Giladi N (2022) The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: findings from the ND0612 clinical development program. Front Neurol 13:1036068

Article  PubMed  PubMed Central  Google Scholar 

Malek N, Grosset DG (2015) Medication adherence in patients with Parkinson’s disease. CNS Drugs 29:47–53

Article  CAS  PubMed  Google Scholar 

Martinez-Nunez AE, LeWitt PA (2023) Drugs to the rescue: comparison of on-demand therapies for off symptoms in Parkinson’s disease. J Parkinsons Dis 13:441–451

Article  PubMed  PubMed Central  Google Scholar 

Meissner W, Reum T, Paul G, Harnack D, Sohr R, Morgenstern R, Kupsch A (2001) Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. Neurosci Lett 303:165–168

Article  CAS  PubMed  Google Scholar 

Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grunblatt E, Riederer P, Jacob C, Haron-Peretz J, Bashenko Y, Youdim MB, Mandel SA (2012) A molecular signature in blood identifies early Parkinson’s disease. Mol Neurodegener 7:26

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller T (2021) View point: disease modification and cell secretome based approaches in Parkinson’s disease: are we on the right track? Biologics 15:307–316

PubMed  PubMed Central  Google Scholar 

Müller T (2022) What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease? Expert Opin Pharmacother 23:745–750

Article  PubMed  Google Scholar 

Müller T, Möhr JD (2024) Negative findings from trials with NLY01 or deferiprone for Parkinson’s disease. Lancet Neurol 23:558–559

Article  PubMed  Google Scholar 

Müller T, Mueller BK, Riederer P (2021) Perspective: treatment for disease modification in chronic neurodegeneration. Cells 10:873

Article  PubMed  PubMed Central  Google Scholar 

Muller-Nedebock AC, Dekker MCJ, Farrer MJ, Hattori N, Lim SY, Mellick GD, Rektorova I, Salama M, Schuh AFS, Stoessl AJ, Sue CM, Tan AH, Vidal RL, Klein C, Bardien S (2023) Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease. NPJ Parkinsons Dis 9:110

Article  PubMed  PubMed Central  Google Scholar 

Mulroy E, Erro R, Bhatia KP, Hallett M (2024) Refining the clinical diagnosis of Parkinson’s disease. Parkinsonism Relat Disord 122:106041

Article  PubMed  Google Scholar 

Natrajan K, Kaushal M, George B, Kanapuru B, Theoret MR (2024) FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-24-0378

Article  PubMed  Google Scholar 

Nijhuis FAP, van den Heuvel L, Bloem BR, Post B, Meinders MJ (2019) The patient’s perspective on shared decision-making in advanced Parkinson’s disease: a cross-sectional survey study. Front Neurol 10:896

Article  PubMed  PubMed Central  Google Scholar 

Nyholm D, Johansson A, Lennernas H, Askmark H (2012) Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur J Neurol 19:820–826

Article  CAS  PubMed  Google Scholar 

Olanow CW, Espay AJ, Stocchi F, Ellenbogen AL, Leinonen M, Adar L, Case RJ, Orenbach SF, Yardeni T, Oren S, Poewe W (2021) Continuous subcutaneous levodopa delivery for Parkinson’s disease: a randomized study. J Parkinsons Dis 11:177–186

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ossig C, Gandor F, Fauser M, Bosredon C, Churilov L, Reichmann H, Horne MK, Ebersbach G, Storch A (2016) Correlation of quantitative motor state assessment using a kinetograph and patient diaries in advanced PD: data from an observational study. PLoS ONE 11:e0161559

Article  PubMed  PubMed Central  Google Scholar 

Poewe W, Stocchi F, Arkadir D, Ebersbach G, Ellenbogen AL, Giladi N, Isaacson SH, Kieburtz K, LeWitt P, Olanow CW, Simuni T, Thomas A, Zlotogorski A, Adar L, Case R, Oren S, Fuchs OS, Rosenfeld O, Sasson N, Yardeni T, Espay AJ (2021) Subcutaneous levodopa infusion for Parkinson’s disease: 1-year data from the open-label BeyoND study. Mov Disord 36:2687–2692

Article  CAS  PubMed  PubMed Central